HC Wainwright Issues Pessimistic Forecast for Century Therapeutics (NASDAQ:IPSC) Stock Price

Century Therapeutics (NASDAQ:IPSC) had its price objective decreased by HC Wainwright from $5.00 to $2.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 355.48% from the company’s previous close.

Several other research analysts also recently commented on the stock. Chardan Capital dropped their price objective on shares of Century Therapeutics from $11.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 24th. Piper Sandler dropped their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday, March 20th. Finally, Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $4.40.

Century Therapeutics Trading Down 4.3 %

NASDAQ:IPSC opened at $0.44 on Thursday. The stock has a 50-day moving average price of $0.66 and a 200 day moving average price of $1.09. The stock has a market capitalization of $37.78 million, a P/E ratio of -0.24 and a beta of 1.75. Century Therapeutics has a 12-month low of $0.42 and a 12-month high of $4.43.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.67 million. On average, research analysts predict that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IPSC. Marshall Wace LLP bought a new stake in Century Therapeutics during the fourth quarter worth approximately $36,000. Jane Street Group LLC boosted its holdings in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares during the period. Two Sigma Advisers LP bought a new position in shares of Century Therapeutics during the 4th quarter valued at approximately $52,000. Sei Investments Co. purchased a new stake in Century Therapeutics during the 4th quarter valued at $53,000. Finally, Two Sigma Investments LP bought a new stake in Century Therapeutics in the fourth quarter worth $67,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.